BridgeBio Pharma (NASDAQ:BBIO) Posts Quarterly Earnings Results, Beats Expectations By $0.12 EPS

BridgeBio Pharma (NASDAQ:BBIO) released its quarterly earnings results on Thursday. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.12, FiscalAI reports. The firm had revenue of $353.17 million for the quarter, compared to the consensus estimate of $293.47 million. The company’s revenue for the quarter was up 192.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.95) earnings per share.

Here are the key takeaways from BridgeBio Pharma’s conference call:

• Attruby U.S. net product revenue rose 134% year over year to $253.2 million, up approximately 14% sequentially, with growth driven primarily by first-line new patient starts. Management expects near-term quarterly increases of roughly $25 million to $30 million and believes the franchise can meet or exceed its $4 billion peak-sales assumption.
• New real-world analyses continued to favor acoramidis over tafamidis, including an 18% lower composite risk in an independent 2,684-patient EHR analysis and 25%-27% lower hospitalization risks. Management said the findings, along with kidney-function and longer-term survival data, are strengthening Attruby’s commercial differentiation.
• BridgeBio highlighted three potential launches within the next seven months: BBP-418 has a November 27, 2026 PDUFA date, infigratinib has a February 4, 2027 date, and encaleret has a May 8, 2027 date. The company said launch teams are deployed, BBP-418 manufacturing is ready, and it expects traditional approval for BBP-418.
• Third-quarter total revenue increased to $353.2 million from $120.7 million, helped by Attruby growth, $20.5 million in royalties, and a one-time $75 million Bayer milestone. Cash and marketable securities reached a record $1.5 billion, which management believes is sufficient to fund operations and the upcoming launches while operating losses improve toward potential profitability across the portfolio by 2028.
• Management emphasized that significant opportunities remain, including more than 60% of U.S. prescribers who have not yet tried Attruby and a potential expansion of encaleret into chronic hypoparathyroidism, a market estimated at roughly 200,000 patients in the U.S. and Europe. However, European filing for BBP-418 is now planned for the first half of 2028 because regulators requested 36-month data, delaying that opportunity relative to the U.S.

BridgeBio Pharma Price Performance

Shares of BridgeBio Pharma stock opened at $70.73 on Friday. The stock has a market cap of $13.83 billion, a price-to-earnings ratio of -19.81 and a beta of 0.97. The firm’s 50-day moving average is $70.43 and its 200 day moving average is $72.85. BridgeBio Pharma has a 1 year low of $60.22 and a 1 year high of $93.42.

Analyst Ratings Changes

A number of analysts have recently commented on BBIO shares. Wells Fargo & Company boosted their target price on shares of BridgeBio Pharma from $98.00 to $102.00 and gave the company an “overweight” rating in a report on Tuesday, August 11th. Bank of America increased their price target on shares of BridgeBio Pharma from $101.00 to $104.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. UBS Group assumed coverage on shares of BridgeBio Pharma in a research report on Thursday, October 15th. They set a “buy” rating and a $92.00 price target for the company. TD Cowen reissued a “buy” rating on shares of BridgeBio Pharma in a research note on Monday, October 5th. Finally, Truist Financial boosted their price objective on shares of BridgeBio Pharma from $102.00 to $107.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $104.63.

BridgeBio Pharma News Summary

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Third-quarter revenue reached $353.2 million, well above the approximately $293.5 million consensus estimate and up 192.6% year over year. BridgeBio Q3 Revenue Earnings Flash
• Positive Sentiment: The company reported a quarterly loss of $0.42 per share, narrower than the $0.54 analyst consensus and significantly improved from a $0.95 loss in the year-earlier period. BridgeBio Q3 EPS Earnings Flash
• Positive Sentiment: U.S. Attruby net product revenue was $253.2 million, increasing approximately $31 million sequentially and $145 million year over year. The results reinforce the commercial momentum of BridgeBio’s primary revenue-generating product. BridgeBio Third-Quarter Results and Corporate Updates
• Positive Sentiment: BridgeBio ended September with $1.5 billion in cash, cash equivalents and marketable securities, which management said fully funds its three launches and expansion indications. This reduces near-term financing and dilution concerns. BridgeBio Cash Position
• Neutral Sentiment: Operating loss was $11.6 million, helped by higher revenue and a one-time $75 million BEYONTTRA sales milestone from Bayer. Investors may therefore distinguish recurring product growth from milestone-related revenue when assessing future quarters. BridgeBio Corporate Updates
• Negative Sentiment: Despite the improvement, BBIO remains unprofitable, and the company’s ability to sustain Attruby growth and execute its multiple launches will remain important to the stock’s valuation.

Insiders Place Their Bets

In other BridgeBio Pharma news, CEO Neil Kumar sold 10,000 shares of BridgeBio Pharma stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $69.08, for a total value of $690,800.00. Following the completion of the transaction, the chief executive officer directly owned 495,686 shares of the company’s stock, valued at approximately $34,241,988.88. The trade was a 1.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 54,980 shares of company stock worth $4,417,999. 14.23% of the stock is currently owned by company insiders.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for genetically driven diseases. The company operates through a portfolio of subsidiary and affiliated biotechnology businesses, with research programs spanning rare diseases, oncology, cardiology and other conditions linked to underlying genetic or molecular causes.

BridgeBio’s portfolio includes therapies designed to address the root mechanisms of disease rather than primarily treating symptoms.